CRYPTOCOCCOSIS IN ADVANCE STATE OF AIDS AND ITS CHALLENGING THERAPEUTIC REGIMEN: IS IT REALLY CURABLE?
Abstract
Cryptococcosis followed by Cryptococcal meningitis (CM) is a deadly disease in an immuno-compromised patient with the complication of advance
human immunodeficiency virus/AIDS, which comes through an air born virus Cryptococcus neoformans, from bird dropping. Immune reconstitution
inflammatory syndrome is also often associated with this disease. A 10 years study showed a 17% prevalence of CM in a tertiary care hospital, among
which 53.1% were infected with AIDS. Treatment guideline is amphotericin B (AmB) and 5-flucytosine or AmB and fluconazole, but the iatrogenic
effect, cost and scarcity of availability of these drugs are the leading cause of mortality due to this disease. Anyhow, various novel therapeutic
approaches have been taken to reduce and/or to prevent the pathogenesis of CM for the sake of mankind.
Keywords: Antiretroviral therapy, Seizures, Hypokalemia, Hypomagnisemia.
Downloads
References
Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sharkey PK, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated Cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992;326(2):83-9.
Bicanic T, Harrison TS. Cryptococcal meningitis. Br Med Bull 2005;72:99-118.
Sloan DJ, Parris V. Cryptococcal meningitis: epidemiology and therapeutic options. Clin Epidemiol 2014;6:169-82.
Loyse A, Thangaraj H, Easterbrook P, Ford N, Roy M, Chiller T, et al. Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. Lancet Infect Dis 2013;13(7):629-37.
George RJ, Jennings AL. Palliative medicine. Postgrad Med J 1993;69(812):429-49.
Hsin IC, Ming YC, Ming KY. Clinically-proven liposome based drug delivery: Formulation, characterization and therapeutic efficacy. Open Access Sci Rep 2012;3(1):2-8.
Hossain MA, Maesaki S, Kakeya H, Noda T, Yanagihara K, Sasaki E, et al. Efficacy of NS-718, a novel lipid nanosphere-encapsulated amphotericin B, against Cryptococcus neoformans. Antimicrob Agents Chemother 1998;42(7):1722-5.
Olson JA, Adler-Moore JP, Jensen GM, Schwartz J, Dignani MC, Proffitt RT. Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products. Antimicrob Agents Chemother 2008;52(1):259-68.
Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003;47(10):3149-54.
Hata K, Kimura J, Miki H, Toyosawa T, Moriyama M, Katsu K. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of Aspergillosis, Candidiasis, and Cryptococcosis. Antimicrob Agents Chemother 1996;40(10):2243-7.
Leite AG, Vidal JE, Bonasser Filho F, Nogueira RS, Oliveira AC. Cerebral infarction related to Cryptococcal meningitis in an HIV-infected patient: case report and literature review. Braz J Infect Dis 2004;8:175-9.
Daneshtalab M. Discovery of chlorogenic acid-based peptidomimetics as a novel class of antifungals. A success story in rational drug design. J Pharm Pharm Sci 2008;11:44s-55.
Joshua R, David RB. Prognosis and management of Cryptococcal meningitis in patients with human immunodeficiency virus infection. Neurobehav HIV Med 2012;4:45-61.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.